A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
A study for patients with advanced or metastatic lung cancer using study drug Nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAO8208
U.S. Govt. ID: NCT02066636
Contact: Natalie Bubsy: 212-304-5579 / nb2718@columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab on patients with advanced or metastatic non-small cell lung cancer . Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the bodys immune system to work against tumor cells. An investigational drug is one that is not approved by the FDA or any other agency and is being studied and developed.
This study is closed
Do You Qualify?
Have you experienced disease progression or recurrence during or after treatment for this disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Natalie Bubsy